Pricing and Reimbursement Regulation in Europe: An Update on the Industry Perspective
Health costs, including the cost of pharmaceuticals, have been rising throughout the world for 35 years. Governments are determined to reduce public expenditure on health; pharmaceuticals are an obvious if frequently an inappropriate target. Cost containment measures include positive and negative lists, permission for more over-the-counter drugs, reference pricing and other price and profit controls, generic substitution, patient copayments, and drug budgets for general practitioners.
These methods have been tried in various European countries and their experiences are reviewed. The advantages and drawbacks of the methods to patients, physicians, and the pharmaceutical industry are discussed. The question of elasticity of demand for pharmaceuticals is reviewed in an Appendix and a value varying between −0.44 and about −1.3 is obtained.
The industry response to cost containment has been mixed. Some of the research-based companies have followed confrontational policies with their governments; others have tried collaborating. Companies aim at “satisficing” the market, that is, making the best profits they can consistent with not generating adverse publicity. The generics companies, which appear at first sight to profit from cost-cutting measures, are actually vulnerable to competition in generics from the research-based companies. Most companies are following policies of risk minimization and this is reflected in the large number of mergers in recent years.
One change that has come about is that policy makers are collaborating internationally. The idea that multinationals can confront governments in Europe is now seen to be untrue, although it may be successful in the United States. The best prospect for pharmaceutical companies is to reach agreements with governments which enable them to flourish if they are innovative and to survive if they are not. This policy has so far been successful, and the industry seems to have emerged largely undamaged from the pressures of the early 1990s.
Unable to display preview. Download preview PDF.
- 2.Burstall ML, Reuben BG. Cost containment in the European pharmaceutical market. London: IMS Marketletter; 1992.Google Scholar
- 3.Burstall ML, et al. The single market review, impact on manufacturing. Volume 2. In: Pharmaceutical Products. Office of Official Publications of the European Communicaties/Kogan Page-Earthscan; 1997.Google Scholar
- 4.Burstall ML. Pricing and reimbursement in Western Europe 1998; A concise guide. Dorking, Surrey, UK: PPR Communications Ltd.; 1998.Google Scholar
- 5.Chalkley M, Robinson R. Cost sharing in health care. London: OHE: 1997.Google Scholar
- 6.Marchant N. Drivers of the growth in medicines expenditure. London: OHE: 1997.Google Scholar
- 7.Schwabe U, Paffrath D. Gesundheitsreformgesseuz und Arzneimitrelversorgung Zwischenbilanz. In: Arzneiverodnungs report ’91. Stuttgart: Gustav Fischer Verlag; 1993.Google Scholar
- 8.Health Economics Centre, Cesav. SCRIP. 1993; 1860:4.Google Scholar
- 9.Reher R, Reichelt H. Sozialer Fortschrit. May 1991;116.Google Scholar
- 10.GP survey in Le Quotidien de Médecin. SCRIP. 1993;1859:7.Google Scholar
- 11.Government Statistical Service. Statistics of prescriptions dispensed in the Community: England 1987-1997. London: Department of Health; 1998.Google Scholar
- 12.Munnich F. IIR’s Pharma Pricing Meeting ’93. Reported in SCRIP. 1993;1861:6.Google Scholar
- 13.Burstall ML, Reuben BG. Critics of the Pharmaceutical Industry. London: REMIT; 1990.Google Scholar
- 14.Lang RW. The Politics of Drugs. Farnborough: Saxon House; 139–188 and 257–292.Google Scholar
- 15.SCRIP. 1993;1861:18.Google Scholar
- 16.Reuben BG. The Times. London. March 3, 1998.Google Scholar
- 17.James BG. Pharm Vision 2005. Massachusetts: Spectrum (Decision Resources); October 1997, 67.Google Scholar
- 18.Green D. Financial Times pharmaceuticals survey. Financial Times. March 16, 1998.Google Scholar
- 19.Reuben BG, Burstall ML. Generic Pharmaceuticals–the Threat. London: Economists Advisory Group; 1989.Google Scholar
- 20.European Commission. Preliminary draft for measures aiming at modifying and completing Directive 89/105/EEC concerning the pricing and reimbursement of medicinal products for human use (111/3749/ 91).Google Scholar
- 21.SCRIP. 1993;1860:3, 1857:2.Google Scholar
- 22.European Commission. Communication from the Commission to the Council and the European Parliament on the outlines of an industrial policy for the European Community. COM(93)718 final 1993.Google Scholar
- 23.Pharmaceuticals Survey. Financial Times. London. March 23, 1994.Google Scholar
- 1.Newhouse JPA. A design for a health insurance experiment. Inquiry. 1974;16:5–27.Google Scholar
- 2.Manning WG, Newhouse JP, Duan N, Keeler E, Lei-bowitz BA, Marquis MS. Health insurance and the demand for medical care: Evidence from a randomized experiment. Am Economic Rev. 1987;77:251–277.Google Scholar
- 6.Chew R, Griffin D. Trends in usage of prescription medicines by the elderly and very elderly between 1977 and 1988. ABPI briefing, London, February 1990.Google Scholar
- 7.Key health statistics for general practice, 1996. London; Office of National Statistics; 1996. www.ons.gov.uk.Google Scholar